New anthrax vaccine under review for Post-Exposure protection
NCT ID NCT07268612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will look at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria during a mass event. Researchers want to see if the vaccine, given along with antibiotics, can prevent inhalational anthrax and anthrax meningitis. The study is observational, meaning it will analyze data from past events rather than testing the vaccine in a new controlled experiment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CYFENDUS anthrax vaccine
- What this could lead to
- If this study shows the vaccine works well, it could confirm a safe and effective way to prevent anthrax after a large-scale exposure.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The study is small and only looks at past events, so it cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTHRAX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.